Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10... BioDrugs (2017) 31:357–367 DOI 10.1007/s40259-017-0232-7 OR IGINAL RESEARCH ARTIC L E Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial 1 2 3 4 • • • • Dae Hyun Yoo Chang-Hee Suh Seung Cheol Shim Slawomir Jeka 5 6 7 • • • Francisco Fidencio Cons Molina Pawel Hrycaj Piotr Wiland 8 9 10 • • • Eun Young Lee Francisco G. Medina-Rodriguez Pavel Shesternya 11 12 13 • • • Sebastiao Radominski Marina Stanislav Volodymyr Kovalenko 14 15 16 17 • • • • Dong Hyuk Sheen Leysan Myasoutova Mie Jin Lim Jung-Yoon Choe 18 18 18 16 • • • Sang Joon Lee Sung Young Lee Sung Hwan Kim Won Park Published online: 13 June 2017 The Author(s) 2017. This article is an open access publication Abstract or RTX 1000 mg at weeks 0 and 2. Based on disease Background CT-P10 is a biosimilar of innovator ritux- activity, patients could receive a second course of treat- imab (RTX), a biological therapy used to treat patients ment between weeks 24 and 48. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioDrugs Springer Journals

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

Loading next page...
 
/lp/springer_journal/efficacy-safety-and-pharmacokinetics-of-up-to-two-courses-of-the-x3d1tDAEdi
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by The Author(s)
Subject
Biomedicine; Molecular Medicine; Antibodies; Cancer Research; Pharmacotherapy
ISSN
1173-8804
eISSN
1179-190X
D.O.I.
10.1007/s40259-017-0232-7
Publisher site
See Article on Publisher Site

Abstract

BioDrugs (2017) 31:357–367 DOI 10.1007/s40259-017-0232-7 OR IGINAL RESEARCH ARTIC L E Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial 1 2 3 4 • • • • Dae Hyun Yoo Chang-Hee Suh Seung Cheol Shim Slawomir Jeka 5 6 7 • • • Francisco Fidencio Cons Molina Pawel Hrycaj Piotr Wiland 8 9 10 • • • Eun Young Lee Francisco G. Medina-Rodriguez Pavel Shesternya 11 12 13 • • • Sebastiao Radominski Marina Stanislav Volodymyr Kovalenko 14 15 16 17 • • • • Dong Hyuk Sheen Leysan Myasoutova Mie Jin Lim Jung-Yoon Choe 18 18 18 16 • • • Sang Joon Lee Sung Young Lee Sung Hwan Kim Won Park Published online: 13 June 2017 The Author(s) 2017. This article is an open access publication Abstract or RTX 1000 mg at weeks 0 and 2. Based on disease Background CT-P10 is a biosimilar of innovator ritux- activity, patients could receive a second course of treat- imab (RTX), a biological therapy used to treat patients ment between weeks 24 and 48.

Journal

BioDrugsSpringer Journals

Published: Jun 13, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off